Skip to main content
Journal ArticleOPEN ACCESS

Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

  • Westerman M
  • Wood C
Annals of Translational Medicine (2020) 8(16) 1037-1037
DOI: 10.21037/atm.2020.03.217
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Provenance and Peer Review: This article was commissioned by the Editorial Office, Annals of Translational Medicine. The article did not undergo external peer review. Comment on: Rini BI, Pal SK, Escudier BJ, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.

Cite

CITATION STYLE

APA

Westerman, M. E., & Wood, C. G. (2020). Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Annals of Translational Medicine, 8(16), 1037–1037. https://doi.org/10.21037/atm.2020.03.217

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free